INTEGRATED SAFETY OF LESINURAD, A NOVEL URIC ACID REABSORPTION INHIBITOR FOR THE TREATMENT OF GOUT

被引：0
|
作者：
Becker, M. A. [1 ]
Keenan, R. T. [2 ]
Khanna, P. P. [3 ]
Malamet, R. [4 ]
Bos, K. [4 ]
Li, J. [4 ]
Hu, J. [5 ]
White, W. B. [6 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] AstraZeneca, Wilmington, DE USA
[5] Formerly Ardea Biosci Inc, San Diego, CA USA
[6] Univ Connecticut, Sch Med, Farmington, CT USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.3674
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0444
引用
收藏
页码：375 / 376
页数：2
相关论文
共 50 条
  • [31] Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout
    Huneycutt, Emily
    Board, Chase
    Clements, Jennifer N.
    JOURNAL OF PHARMACY PRACTICE, 2018, 31 (06) : 670 - 677
  • [32] Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition
    Tan, Philip K.
    Hyndman, David
    Miner, Jeffrey N.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S731 - S731
  • [33] Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney (vol 18, 214, 2016)
    Miner, Jeffrey N.
    Tan, Philip K.
    Hyndman, David
    Liu, Sha
    Iverson, Cory
    Nanavati, Payal
    Hagerty, David T.
    Manhard, Kimberly
    Shen, Zancong
    Girardet, Jean-Luc
    Yeh, Li-Tain
    Terkeltaub, Robert
    Quart, Barry
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [34] Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout
    Hill-McManus, Daniel
    Soto, Elena
    Marshall, Scott
    Lane, Steven
    Hughes, Dyfrig
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (01) : 142 - 152
  • [35] The Effect of Uric Acid Lowering Treatment on the Microbiome in Gout Patients
    Kim, Hye Won
    Yoon, Eun-Jeong
    Jeong, Seok Hoon
    Park, Min-Chan
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [36] LESINURAD SODIUM Solute Carrier Family 22 Member 12 (URATI) Inhibitor Uricosuric Treatment of Gout
    Pema, K. M.
    DRUGS OF THE FUTURE, 2011, 36 (12) : 875 - 880
  • [37] RENAL FUNCTION IN GOUT .3. ESTIMATION OF TUBULAR SECRETION AND REABSORPTION OF URIC ACID BY USE OF PYRAZINAMIDE (PYRAZINOIC ACID)
    GUTMAN, AB
    YU, TF
    BERGER, L
    AMERICAN JOURNAL OF MEDICINE, 1969, 47 (04): : 575 - +
  • [38] Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
    William B. Smith
    Jesse Hall
    Jolene K. Berg
    Michal Kazimir
    Amy Yamamoto
    Susan Walker
    Caroline A. Lee
    Zancong Shen
    David M. Wilson
    Dongmei Zhou
    Michael Gillen
    Thomas C. Marbury
    Clinical Drug Investigation, 2018, 38 : 703 - 713
  • [39] Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
    Smith, William B.
    Hall, Jesse
    Berg, Jolene K.
    Kazimir, Michal
    Yamamoto, Amy
    Walker, Susan
    Lee, Caroline A.
    Shen, Zancong
    Wilson, David M.
    Zhou, Dongmei
    Gillen, Michael
    Marbury, Thomas C.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (08) : 703 - 713
  • [40] Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
    Dalbeth, Nicola
    Jones, Graeme
    Terkeltaub, Robert
    Khanna, Dinesh
    Fung, Maple
    Baumgartner, Scott
    Perez-Ruiz, Fernando
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
12345